COMPANY:

Velsera

"Velsera...has partnered with Diagnostic Longwood...This collaboration is set to accelerate the adoption of precision medicine in Spain and Portugal by integrating Velsera's Clinical Genomics Workspace (CGW) platform with Diagnostics Longwood's deep regional expertise and distribution network."

"Velsera...announce that our advanced tumor profiling technology is a key component of the knowledge base that supports the Illumina TruSight™ Oncology (TSO) Comprehensive IVD results report. The knowledge base of TSO Comprehensive integrates Velsera's cutting-edge tumor profiling technology, enhancing patient care by enabling personalized treatment nationwide."

"Arima Genomics, Inc...and Pierian now a part of Velsera...announced co-marketing and licensing agreements that will provide enhanced gene fusion detecting capabilities to clinical labs. Under the terms of the agreement, Velsera will integrate Arima Genomics’ targeted next-generation sequencing (NGS) testing pipelines into the Pierian Clinical Genomics Workspace (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting. The combined solution will enable clinical laboratories to more easily implement sample-to-answer Arima gene fusion testing, helping them identify gene fusions and other structural variants."

"Healthcare and life science firms Pierian, Seven Bridges, and UgenTec have been acquired by investment fund Summa Equity for an undisclosed amount and merged to form a new precision medicine company, Velsera. The creation of the new company was announced...at the JP Morgan Healthcare Conference."

"PreCheck Health Services, Inc...announced a collaboration with Pierian...to provide in-house next-generation sequencing (NGS) services that support cancer-related genetic testing for medical facilities and patients in South Florida with plans to expand nationwide."

"Pierian®...is pleased to announce an exciting partnership with P4 Diagnostix®...Now physician-owned laboratories (POLs) that specialize in urology, gastroenterology, or women’s health, can add next-generation sequencing (NGS) testing for hereditary cancer to their routine diagnostic practice."

"Laboratory network P4 Diagnostix...has entered into a partnership with software firm Pierian to offer somatic prostate cancer testing...The companies will use the Illumina TruSight Oncology 500 cancer panel to add somatic testing to P4's current UroSeq next-generation sequencing-based germline testing product."

"Syapse, a leading real-world evidence company announced with Pierian, a global leader in advanced clinical genomics technology, a new joint collaboration that will benefit patients of the AdventHealth Cancer Institute in Central Florida. The collaboration combines Syapse’s real-world evidence solutions designed to improve outcomes for patients with cancer, Pierian’s leading-edge clinical genomics workflow, and precision medicine services that provide the most relevant insights in the industry. This partnership will enable AdventHealth clinicians to offer more comprehensive diagnostics for oncology patients in Central Florida, allowing more personalized treatment options due to improved capabilities to identify known and emerging biomarkers critical for cancer treatment and progression."

"PierianDx...today announced that it has partnered with Biodesix to provide its interpretation technology platform for use with the Biodesix newly launched GeneStrat NGS™ genomic test, a blood-based tumor profiling test to detect actionable mutations in patients with non-small cell lung cancer (NSCLC)....The IQLung strategy uses genomic profiling to detect actionable mutations in lung cancer, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner."